NEWS

Pharmaceutical Industry news helps our clients to give competitive edge to their customers and also latest pharmaceutical industry news assists them in gaining updated knowledge. We bring you Global Pharmaceutical news about acquisitions, project undertakings, business and marketing, subjects, and industry related subjects, written in a professional, unbiased and thought-provoking format. Our international pharmaceutical News will help you enhance your business knowledge and productivity.

Autolus, a U.K.-based biopharmaceutical company focused on discovering and developing treatments for cancer, will locate its 85,000 square foot U.S. headquarters, manufacturing and R&D complex in Rockville, Maryland. A leader in T-cell programming and manufacturing technology, the company plans to create approximately 170 new jobs by 2021. “Autolus is delighted…

Veritas Pharma Inc is pleased to announce that it has entered into a Memorandum of Understanding (“MOU”) with Santa Marta Gold Holdings Ltd. (“Santa Marta”) where both companies will share the intellectual property (“IP”) jointly developed as part of a proposed agreement that outlines a medical cannabis research collaboration. Under…

Johnson & Johnson raised U.S. prices on around two dozen prescription drugs on Thursday, including the psoriasis treatment Stelara, prostate cancer drug Zytiga and blood thinner Xarelto, all among its top-selling products. J&J joined many other companies that raised U.S. prices on hundreds of prescription medicines earlier this month. Most…

On the final day of the largest biotechnology and pharmaceutical partnering week at the Juvenescence Longevity Showcase two leading longevity biotechnology companies, Elevian and Insilico Medicine, announced a research and development partnership to develop oral medications targeting the GDF11 pathway and associated targets. Elevian is an emerging biotech company developing…

Selexis SA, a pioneering life sciences company and a global leader in mammalian cell line generation technology, announced today that it has signed additional commercial license agreements (CLAs) with Agenus Inc.,, an immuno-oncology company with a pipeline of immune-modulating antibodies, cancer vaccines, and adoptive cell therapies. Under the new CLAs,…

CANbridge Pharmaceuticals Inc., a biopharmaceutical company developing innovative drug candidates to treat underserved medical conditions in China and other markets, and WuXi Biologics (2269. HK), a leading global open-access biologics technology platform company offering end-to-end solutions for biologics discovery, development and manufacturing, jointly announced an expansion of their rare disease…

Cannapharmarx, Inc.announced today it has completed the acquisition of Alternative Medical Solutions, Inc., ("AMS"), an Ontario, Canada corporation. Under the terms of the agreement Hanover CPMD Acquisition Corp. ("HCAC"), a wholly-owned subsidiary of the Company, acquired all of the issued and outstanding securities of AMS for total consideration of CAD$12,710,000…

CytoReason, a leader in machine learning for drug discovery and development, announced today that it has entered into a collaboration agreement with Pfizer Inc.  that will leverage CytoReason’s cell-centered models of the immune system. CytoReason will receive from Pfizer payments potentially equaling up to low double digit millions of US$…

Sigilon Therapeutics, a biopharmaceutical company that discovers and develops Shielded Living Therapeutics, and the Massachusetts Institute of Technology today announced a strategic research collaboration. The collaboration leverages cutting-edge synthetic biology approaches developed by professor Ron Weiss of the MIT Synthetic Biology Center, an internationally recognized leader in the field of…

Biogen  Inc and Skyhawk Therapeutics, Inc. today announced a strategic collaboration in which both companies will take advantage of the platform SkySTAR ™ technology with the aim of discovering innovative treatments of small molecules for patients suffering from neurological diseases. Biogen will have the option to license the treatments resulting…

loadmore..